So far, an analysis of a PAM50 assay (including 50 breast cancer-related genes) of 3600 patients by Schettini et al. elucidated that hormone receptor positive/HER2low tumors had a higher ERBB2 expression level than HER2- tumors5. This evidence concerns the gene ERBB2 and breast cancer.